Literature DB >> 27658315

Clinical Trials Registration and Results Information Submission. Final rule.

.   

Abstract

This final rule details the requirements for submitting registration and summary results information, including adverse event information, for specified clinical trials of drug products (including biological products) and device products and for pediatric postmarket surveillances of a device product to ClinicalTrials.gov, the clinical trial registry and results data bank operated by the National Library of Medicine (NLM) of the National Institutes of Health (NIH). This rule provides for the expanded registry and results data bank specified in Title VIII of the Food and Drug Administration Amendments Act of 2007 (FDAAA) to help patients find trials for which they might be eligible, enhance the design of clinical trials and prevent duplication of unsuccessful or unsafe trials, improve the evidence base that informs clinical care, increase the efficiency of drug and device development processes, improve clinical research practice, and build public trust in clinical research. The requirements apply to the responsible party (meaning the sponsor or designated principal investigator) for certain clinical trials of drug products (including biological products) and device products that are regulated by the Food and Drug Administration (FDA) and for pediatric postmarket surveillances of a device product that are ordered by FDA.

Entities:  

Mesh:

Year:  2016        PMID: 27658315

Source DB:  PubMed          Journal:  Fed Regist        ISSN: 0097-6326


  39 in total

1.  Reaping the Bounty of Publicly Available Clinical Trial Consent Forms.

Authors:  Holly Fernandez Lynch; Emily A Largent; Deborah A Zarin
Journal:  IRB       Date:  2017 Nov-Dec

2.  New requirements for clinical trial transparency provide new opportunities for informatics research.

Authors:  Betsy L Humphreys
Journal:  J Am Med Inform Assoc       Date:  2019-06-01       Impact factor: 4.497

3.  Toward a New Era of Trust and Transparency in Clinical Trials.

Authors:  Kathy L Hudson; Michael S Lauer; Francis S Collins
Journal:  JAMA       Date:  2016-10-04       Impact factor: 56.272

4.  Trial Reporting in ClinicalTrials.gov - The Final Rule.

Authors:  Deborah A Zarin; Tony Tse; Rebecca J Williams; Sarah Carr
Journal:  N Engl J Med       Date:  2016-09-16       Impact factor: 91.245

5.  Unfounded Claims of Improved Functional Outcomes Attributed to Follistatin Gene Therapy in Inclusion Body Myositis.

Authors:  Steven A Greenberg
Journal:  Mol Ther       Date:  2017-09-08       Impact factor: 11.454

Review 6.  Standards for design and measurement would make clinical research reproducible and usable.

Authors:  Kay Dickersin; Evan Mayo-Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-13       Impact factor: 11.205

7.  ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors.

Authors:  Annie Yang; Shrujal Baxi; Deborah Korenstein
Journal:  J Oncol Pract       Date:  2018-01-03       Impact factor: 3.840

Review 8.  Legal regulations, ethical guidelines and recent policies to increase transparency of clinical trials.

Authors:  Jan Borysowski; Agata Wnukiewicz-Kozłowska; Andrzej Górski
Journal:  Br J Clin Pharmacol       Date:  2020-02-19       Impact factor: 4.335

9.  An Institutional Program to Increase Compliance with Clinicaltrials.gov Requirements.

Authors:  Issis Kelly-Pumarol; Joseph E Andrews
Journal:  Ther Innov Regul Sci       Date:  2018-05-28       Impact factor: 1.778

Review 10.  AAN position statement: Ethical issues in clinical research in neurology.

Authors:  Benjamin Tolchin; Robin Conwit; Leon G Epstein; James A Russell
Journal:  Neurology       Date:  2020-03-16       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.